Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654343 | 1.00 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11407090 | 1.00 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10528749 | 1.00 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3137204 | 0.97 | ADH1B (0.39) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4653000 | 0.97 | ADH1B (0.32) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3166187 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2359513 | 0.94 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL8670105 | 0.92 | ADH1B (0.32) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4578985 | 0.92 | — | — | |
| SCHEMBL1758252 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | claimed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | claimed |
| EP-0259752-A2 | Saccharide phosphates, their esters and method for their preparation | BAYER AG (DE) | 1988-03-16 | — | — | EP | claimed |
| EP-0042659-B1 | 5,6,6A,7-TETRAHYDRO-4H-DIBENZ(DE,G)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1984-08-29 | — | — | EP | claimed |
| EP-4281072-A1 | FERROPORTIN-INHIBITORS FOR THE USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) | VIFOR (INTERNATIONAL) AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20220273634-A1 | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) | VIFOR (INTERNATIONAL) AG (CH) | 2022-09-01 | — | — | US | disclosed |
| EP-3999060-A1 | FERROPORTIN-INHIBITORS FOR THE USE IN THE PREVENTION AND TREATMENT OF KIDNEY INJURIES | VIFOR (INTERNATIONAL) AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| US-11129820-B2 | Ferroportin-inhibitor salts | VIFOR (INTERNATIONAL) AG (CH) | 2021-09-28 | — | — | US | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-4686208-A | Phosphorylated glycosyl-amides, -ureas, -carbamates and -thiocarbamates and method of use | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | disclosed |
| EP-0193887-A2 | Substituted O-sulfonyl-glycosyl amides, method for their preparation and their use as mediacments | BAYER AG (DE) | 1986-09-10 | — | — | EP | disclosed |
| US-4574122-A | ANTIBODIES, IMMUNOLOGY | BAYER AKTIENGESELLSCHAFT (DE) | 1986-03-04 | — | — | US | disclosed |
| EP-0155625-A2 | Glycolipid-like substances in liposome form | BAYER AG (DE) | 1985-09-25 | — | — | EP | disclosed |
| EP-0149760-A2 | Substituted O-acyl glycosylamides, methods for their preparation and their use | BAYER AG (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0149093-A2 | N-glycosylated ureas, carbamates and thiocarbamates, their preparation method and their use | BAYER AG (DE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0144894-A2 | Therapeutic application of substituted O-acyl-glycosides | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0143385-A2 | Phosphorylised glycosil amides, ureas, carbamates and thiocarbamates, method for their preparation and their use | BAYER AG (DE) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273634-A1 | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) | SLC40A1, FECH, TFRC | ADH1B 361/4885ADH1C 1222/4885ADH1A 748/4885 |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | ADH1B 1082/4885ADH1C 1699/4885ADH1A 1474/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | ADH1B 892/4885ADH1C 1504/4885ADH1A 1323/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | ADH1B 892/4885ADH1C 1504/4885ADH1A 1323/4885 |
| US-11129820-B2 | Ferroportin-inhibitor salts | SLC40A1, HAMP, FECH | ADH1B 872/4885ADH1C 1475/4885ADH1A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.